Pregnancy loss and thrombophilia Plausible biology of beneficial effect of antithrombotic agents Prognosis of live birth without pharmacological treatment after pregnancy loss Clinical studies investigating the efficacy of antithrombotic agents for pregnancy loss † Testing for thrombophilia † Future perspectives † Conclusions background: Although an association between thrombophilia and pregnancy loss has been observed in many studies, little is known about the pathophysiological mechanisms behind this association. Considering the association between thrombophilia and pregnancy loss, the efficacy of antithrombotic therapy for women with pregnancy loss (with or without thrombophilia) has been studied for the past 30 years.
results:
The association between pregnancy loss and thrombophilia varies according to the type of thrombophilia (e.g. antiphospholipid syndrome versus forms of inherited thrombophilia) and according to the type of pregnancy loss (single versus recurrent pregnancy loss and early versus late pregnancy loss).
Thrombophilia may induce thrombosis in decidual vessels or impair placentation through hypercoagulability and inflammation, but these hypotheses need further verification.
For women with antiphospholipid syndrome, evidence from small-sized trials suggests a beneficial effect of antithrombotic therapy but additional randomized controlled trials are essential to confirm this. Whether antithrombotic therapy increases the chance of live birth in women with inherited thrombophilia is unknown. Recent randomized controlled trials have consistently shown that antithrombotic therapy does not increase the chance of live birth in women with unexplained recurrent miscarriage.
Introduction
Pregnancy loss is common; 15% of women experience a single spontaneous loss (Stirrat, 1990; Regan and Rai, 2000) . This percentage reflects only clinically recognized pregnancies. Since pregnancy losses which occur at a very early gestation go unnoticed, the actual percentage of pregnancy loss is estimated to be even higher.
Depending on the gestational age at which pregnancy loss occurs, different terminologies for pregnancy loss are employed. The term miscarriage is often used to define pregnancy loss from the time of conception until 20 weeks' gestation (Zegers-Hochschild et al., 2009 ). Pregnancy loss thereafter is then termed fetal death or stillbirth (Zegers-Hochschild et al., 2009) . Revised terminology by the European Society of Human Reproduction and Embryology defines 'early pregnancy loss' for loss of fetal heart activity prior to 12 weeks' gestation and 'late pregnancy loss' for loss of fetal heart activity at or after 12 weeks' gestation (Table I ; Farquharson et al., 2005) . This classification of pregnancy loss according to gestational age is chosen since the incidence in the first trimester is higher and the pathophysiology is different from losses occurring at a later gestational age. The great majority of pregnancy losses occur early, before 12 weeks' gestation (Brigham et al., 1999) .
The definition of recurrent miscarriage is a subject of debate. The Royal College of Obstetrics and Gynaecologists (RCOG) regards three or more first trimester miscarriages as recurrent pregnancy loss, whereas in Dutch and American guidelines, two or more pregnancy losses are considered recurrent pregnancy loss (Table I ; Royal College of Obstetricians and Gynaecologists, 2011; ASRM, 2013) . When defined as two or more losses, recurrent pregnancy loss affects up to 3% of fertile couples, whereas 1% experience three or more pregnancy losses . Another discrepancy between guidelines and practice statements is the inclusion of the criterion 'consecutive'. Although the American Society for Reproductive Medicine (ASRM) does not incorporate 'consecutive' in its definition of recurrent pregnancy loss, evaluation of pregnancy loss is suggested 'after two consecutive clinical pregnancy losses' (ASRM, 2012 (ASRM, , 2013 . More evidence is available now that recurrent miscarriage constitutes any two miscarriages (Jaslow et al., 2010) . The prevalence of carrier status of structural balanced chromosome abnormalities and antiphospholipid antibodies is similar in couples with a history of two or more consecutive or nonconsecutive pregnancy losses (van den Boogaard et al., 2010 (van den Boogaard et al., , 2013 .
These differences in nomenclature are relevant, as a number of diagnostic tests are performed once the diagnosis of recurrent pregnancy loss is confirmed. Where possible, we describe the type of pregnancy loss in more detail, e.g. single miscarriage, recurrent miscarriage, biochemical pregnancy together with the definition as mentioned in the study, but this is not always possible.
A majority of pregnancy losses that occur before 10 weeks' gestation are due to chromosomal errors arising from non-inherited, nondisjunctional events (Sierra and Stephenson, 2006) . Late pregnancy losses (e.g. .24 weeks' gestation) occur sporadically and are more often due to maternal factors, such as pre-eclampsia. Despite a diagnostic work-up, in 50% of the cases no cause can be identified. Uterine, hormonal and chromosomal abnormalities, endocrine and immune disorders have all been associated with (recurrent) pregnancy loss.
Maternal age is the most important risk factor for pregnancy loss and likely reflects the prevalence of underlying random numeric chromosome errors; the probability of pregnancy loss is around 9% in women aged 20-24 and increases to over 50% in women who are older than 42 years (Nybo Andersen et al., 2000) . Although after a first pregnancy loss the chance of live birth in a subsequent pregnancy is similar to the chance of live birth for primigravidae, it decreases with an increasing number of previous pregnancy losses (Brigham et al., 1999) .
The psychological distress induced by experiencing recurrent pregnancy loss is high (Klock et al., 1997; Lok and Neugebauer, 2007) . Hence, interventions to improve the chance of a live birth of otherwise normal embryos are urgently sought.
This review focuses on antithrombotic agents such as unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and aspirin which may increase the chance of live birth in some, but definitely not all, women. A beneficial effect of antithrombotic agents, heparin in particular, in women with recurrent pregnancy loss was hypothesized as early as 1980 (Langer et al., 1980) . In the past three decades, several studies have investigated the effect of antithrombotic agents on the chance of live birth in women with pregnancy loss. These studies have been performed in various subgroups of women: single or recurrent pregnancy loss, early or late pregnancy loss, pregnancy loss associated with thrombophilia or unexplained recurrent pregnancy loss. Despite these efforts to gain evidence, treatment with antithrombotic agents to improve the chance of live birth is still controversial for most women with pregnancy loss. Here, we discuss the currently available evidence for treatment with antithrombotic agents in women with a single or recurrent pregnancy loss.
Methods
For this comprehensive review, we searched Pubmed to identify relevant articles. We used combinations of the following search terms: 'anticoagulants', 'heparin', 'low-molecular-weight heparin', 'aspirin', 'association', 'pregnancy complications', 'fetal death', 'pregnancy loss', 'pregnancy outcome', 'prognosis', 'thrombophilia' and 'antiphospholipid syndrome'. Reference lists of identified articles were scanned for relevant citations. For studies describing prognosis of pregnancy after pregnancy loss, only contemporary studies were considered (i.e. published from 1995 onward).
Results

Pregnancy loss and thrombophilia
Association
Pregnancy loss occurs more frequently in women with thrombophilia, and the strengths of the associations are summarized in Table II (Robertson et al., 2006; Bates et al., 2012) . The term thrombophilia is used to describe 'endogenous' risk factors for venous thromboembolism. Thrombophilia can be acquired or inherited, and can be identified in approximately half of all patients with venous thromboembolism.
Acquired thrombophilia comprises the antiphospholipid syndrome that consists of clinical criteria combined with persistent presence of laboratory abnormalities, e.g. lupus anticoagulant, antibodies against cardiolipin or antibodies against beta 2 glycoprotein I, tested at least 12 weeks apart (Miyakis et al., 2006; de Groot and Meijers, 2011 The data on the use of anticoagulants for the treatment of RM in women without APS are too limited to recommend their routine use within this context APLA, antiphospholipid antibodies; APS, antiphospholipid syndrome; GA, gestational age; LMWH, low-molecular-weight heparin; RCT, Randomized controlled trial. The RCOG classifies levels of evidence from 4 (expert opinion only) through 1++ (high-quality meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with a very low risk of bias). RCOG recommendations are based on these levels of evidence and graded as follows: A: At least one meta-analysis, systematic review or randomized controlled trial rated as 1++ and directly applicable to the target population; or a systematic review of randomized controlled trials or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results. B: A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results;or extrapolated evidence from studies rated as 1++ or 1+. C: A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results;or extrapolated evidence from studies rated as 2++. D: Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+. Good practice point: Recommended best practice based on the clinical experience of the guideline development group. The ASRM practice committee does not grade the available evidence but refers to original studies only. The ACCP gives recommendations from 1A to 2C. The number (1 or 2) refers to the strength of the recommendation (1: strong recommendation, 2: weak recommendation), and the letters (A, B or C) indicate the quality of the evidence on which the the recommendation is based (A: high-quality evidence, B: moderate quality evidence, C: low-quality evidence) (Guyatt et al., 2012) .
pregnancy morbidity, defined as three or more unexplained pregnancy losses before 10 weeks' gestation, one or more unexplained intrauterine fetal death beyond 20 weeks' gestation or one or more premature birth before 34 weeks' gestation, due to eclampsia, severe preeclampsia or recognized features of placental insufficiency (Miyakis et al., 2006) . Antiphospholipid syndrome is an example of a syndrome that has been defined without understanding the etiology of the disease, based solely on the observation that young individuals with systemic lupus erythematosus often suffer from unprovoked thrombosis or unexplained pregnancy losses and show the presence of antiphospholipid antibodies in their plasma (Hughes et al., 1986) .
Inherited thrombophilia comprises deficiencies of the natural anticoagulant proteins, antithrombin, protein C or protein S, that downregulate the formation of thrombin, or the gain of function mutations in coagulation factors Va (leading to activated protein C resistance, factor V Leiden) and prothrombin (prothrombin G20210A mutation; Middeldorp and Levi, 2007) . In the 1990s, inherited thrombophilia was also found to be associated with recurrent pregnancy loss, late pregnancy loss and pre-eclampsia (Preston et al., 1996; Sanson et al., 1996; Meinardi et al., 1999; Rey et al., 2003; Robertson et al., 2006; Middeldorp, 2007; Rodger et al., 2008) .
Pathophysiology
The association between thrombophilia and pregnancy loss has been identified, but the underlying mechanism remains unclear. One presumption was that pregnancy loss might be caused by thrombosis in decidual vessels (Lockshin, 1999) . However, the concept that recurrent pregnancy loss and pre-eclampsia can be attributed to thrombosis is likely to represent an oversimplification.
Coagulation and inflammation are closely related pathways (Esmon et al., 1991) and several observations have implicated a role for both procoagulant and inflammatory pathways in pregnancy failure (Esmon et al., 1991; Kwak-Kim et al., 2009) . Inflammatory changes are essential for the various processes of successful embryonic implantation, such as trophoblast invasion, angiogenesis and placental growth, but how the initial inflammatory response during the implantation period is controlled to protect the semi-allogenic fetus is poorly understood. In procoagulant thrombomodulin-deficient mice, activated coagulation factors induce cell death and inhibit the growth of trophoblast cells (Isermann et al., 2003) . In vitro experiments have shown that antiphospholipid antibodies prevent extravillous trophoblast differentiation (Quenby et al., 2005) . In addition, antiphospholipid antibodies are thought to disrupt crystallization of Annexin A5, thereby limiting its anticoagulant properties (Rand et al., 2003 (Rand et al., , 2004 . Furthermore, in mice, antiphospholipid antibodies induce complement activation, the degree of which is closely correlated to fetal death (Girardi et al., 2004) . In an observational study, levels of circulating procoagulant microparticles were higher in women with recurrent early miscarriage when compared with controls (Laude et al., 2001) .
These observations clearly indicate a role for both coagulation and inflammation, but a better understanding of the underlying mechanisms and, most notably, translation to the human situation of implantation and pregnancy failure is urgently needed.
Plausible biology of beneficial effect of antithrombotic agents
In light of the presumed pathophysiology of the association between pregnancy loss and thrombophilia, the hypothesis of a beneficial effect of antithrombotic agents has arisen. The mechanism of action of heparin is mostly attributed to its anticoagulant activity, a result of binding to and potentiating the action of antithrombin (Hirsh et al., 2001 ). This anticoagulant activity may reduce thrombosis in the (micro) vasculature of the placenta. In addition, blockage of adhesion proteins (selectins) is an anti-inflammatory property of heparin on tumor cell lines in vitro . The clinical relevance of this in pregnancy is uncertain, as proper expression and interaction of adhesive molecules is essential for successful implantation. Furthermore, heparin promotes extravillous trophoblast differentiation in placental tissue in vitro (Quenby et al., 2004) , although the effect on throphoblast differentiation varies between UFH and LMWH. LMWH reduces antiphospholipid antibody binding to trophoblast cells in vitro (Di Simone et al., 1999) . The mechanism of effect of aspirin to increase the chance of live birth in women with pregnancy loss is less clear. As a platelet inhibitor, aspirin may reduce coagulation activity in the placenta. Proteaseactivated receptors (PARs) play a role in coagulation and thrombin mediates activation of platelets via PAR-4. As mentioned previously, in thrombomodulin-deficient mice, trophoblast development is inhibited. PAR-4 deficiency of the mother or the absence of maternal platelets restores normal development in one-third of thrombomodulindeficient embryos (Sood et al., 2008) . This indicates that PAR-4-mediated activation of maternal platelets is a likely mechanism responsible for fetal loss in this mouse model. Inhibition of platelets by aspirin is therefore hypothesized to reduce placental coagulation and may contribute to successful placental development.
It was demonstrated in murine models that appropriate complement regulation is necessary to control placental inflammation and that a local increase in complement activation fragments is highly deleterious to the developing fetus (Salmon et al., 2002) . It is proposed that antiphospholipid antibodies, in addition to their direct effects on platelet and endothelial cell targets, generate complement split products, which ultimately lead to fetal loss in the obstetric antiphospholipid syndrome Salmon et al., 2002) . As coagulation is intertwined with the immune system (Delvaeye and Conway, 2009) , deleterious effects of coagulation, which in turn may be activated by the complement system, may be inhibited by platelet aggregation inhibitors such as aspirin.
Prognosis of live birth without pharmacological treatment after pregnancy loss Table III summarizes the results from contemporary observational studies investigating the prognosis of live birth without pharmacological treatment in women with previous pregnancy loss. We have categorized studies for women with antiphospholipid antibodies (not always fulfilling all criteria for antiphospholipid syndrome), and those with and without inherited thrombophilia. Furthermore, if possible, we categorized the type of pregnancy loss: early versus late and single versus recurrent. Live birth rates vary between 0 and 99%, indicating the difficulty in drawing conclusions. Study populations vary and, perhaps more importantly, the onset of follow-up differs per study. It appears that live birth rates in women recruited in very early pregnancy, e.g. from 5 weeks amenorrhea, are substantially lower than in women who are recruited from 12 weeks' gestation. This is likely explained by the fact that women with early miscarriages are not included in the latter study population.
Clinical studies investigating the efficacy of antithrombotic agents for pregnancy loss
Despite the uncertainty of prognosis after pregnancy loss and the mechanisms of action, physicians frequently prescribe antithrombotic agents in pregnancy. Of note, beneficial effects of antithrombotic agents are frequently suggested by results from observational studies that have intrinsic methodological issues undermining their validity to assess efficacy of an intervention. Although clinical trials have been performed, these are generally limited by small sample sizes and often lack a control arm without active intervention.
As described above, pregnancy loss is not a homogeneous disorder. Recurrence of pregnancy loss as well as the presence of thrombophilia may identify women with pregnancy loss who are more likely to benefit from antithrombotic agents than others. In the following section, we distinguish four groups: (i) women with antiphospholipid syndrome; (ii) women with one previous pregnancy loss and inherited thrombophilia; (iii) women with recurrent pregnancy loss and inherited thrombophilia; and (iv) women with unexplained recurrent pregnancy loss. Table IV summarizes the trials.
Obstetric antiphospholipid syndrome
Single pregnancy loss. Clinical trials on antithrombotic agents that exclusively included women with antiphospholipid syndrome based on the clinical criterion of one late previous pregnancy loss have not been performed.
Recurrent pregnancy loss. Clinical trials that have investigated the efficacy of antithrombotic therapy in women with recurrent pregnancy loss and antiphospholipid syndrome are few and have been summarized in a Cochrane systematic review (Empson et al., 2005) . Two more recent systematic reviews have addressed the efficacy of heparin combined with aspirin versus aspirin only (Mak et al., 2010; Ziakas et al., 2010) .
Aspirin only
The pooled results of three very small trials (total number of 71 participants) showed no effect of aspirin only when compared with no treatment [relative risk (RR) of pregnancy loss of 1.05, 95% confidence interval (CI) 0.66-1.68] (Empson et al., 2005) .
Heparin only: A recent trial compared the efficacy of the LMWH (bemiparin 2500 U once daily, n ¼ 80) with aspirin 100 mg (n ¼ 61) in women with at least two consecutive miscarriages ,20 weeks' gestation (Alalaf, 2012) . Results suggest a beneficial effect of bemiparin over aspirin (RR for live birth for women treated with bemiparin 1.20, 95% CI 1.00-1.43). The allocation was not concealed, as the study was quasi-randomized (sequential assignment of treatment) and for unclear reasons more women were allocated to bemiparin compared with aspirin.
Heparin combined with aspirin: The evidence for a beneficial effect is strongest for treatment with UFH combined with aspirin when compared with aspirin only, in women with recurrent pregnancy loss and antiphospholipid syndrome. Results of one meta-analysis showed that in women with two or more pregnancy losses, treatment with UFH combined with aspirin (n ¼ 103) reduced the chance of first trimester miscarriage when compared with aspirin only (n ¼ 109; RR The studies by Rai (1995) , , Rai (2002) , Coppens (2007) , Lindqvist (2006) , Sugiura-ogasawara (2008), Chauleur (2010) and Lund (2010) investigated multiple cohorts; and are separately discussed in this table. Data for the study by Lindqvist and Merlo (2006) was not available from the paper, but provided by Dr Lindqvist as a personal communication. Study population was a subgroup of a cohort study (Lindqvist et al., 1999) including 2480 gravidae; recruited at a mean of 12 weeks of gestation. AB2GP1, anti-beta 2 glycoprotein 1 antibodies; ACA, anticardiolipin antibodies; APS, antiphospholipid syndrome; FVL, factor V Leiden; GA, gestational age; LA, lupus anticoagulant; PTM, prothrombin G20210A mutation; NA, not available. a Age is presented as mean (+ standard deviation) or median (range) as reported in original study reports. If age was not specified for subgroups, age for the original total cohort is given.
b Mean age at the time of first pregnancy.
c Description of onset of follow-up was not often clearly described in original study reports; quoted from the original articles. Inclusion criterion of a minimum of three consecutive losses was irrespective of gestational age, but the median number of late miscarriages (14 -21 + 6 weeks' GA) and stillbirths (after 22 weeks' GA) was 0. The study by Tulppala (1997) investigated both women with and without antiphospholipid antibodies; and these groups are discussed separately in this table. The study by Brenner (2005) included women with inherited thrombophilia, antiphospholipid antibodies, The study by Laskin (2009) included women with recurrent pregnancy loss and antiphospholipid antibodies, inherited thrombophilia, or antinuclear antibodies; only the subgroup of women with antiphospholipid antibodies was included in the table. The study by Giancotti (2012) included women with unexplained recurrent miscarriage, as well as women with recurrent miscarriage associated with antiphospholipid antibodies or inherited thrombophilia; the subgroup of women with antiphospholipid antibodies was excluded from this Table. Policy for prospective trial registration commenced on 1 July 2005 (de Angelis et al., 2004) . This was not operative at time trials by Tulppala (1997) , Dolitzky (2006) , Kutteh (1996) , Kutteh (1996) , , Pattison (2000) , Farquharson (2002) , Stephenson (2004) , Brenner (2005) and Noble (2005) were conducted. Data for this table on live birth were provided by study authors for the studies by Badawy (2008) and Giancotti (2012) (personal communication) . UFH, unfractionated heparin; LMWH, low-molecular-weight heparin; PTT, prothrombin time; GA, gestational age. a Criteria for antiphospholipid syndrome vary per study. The risk of bias in individual studies was determined according to the Cochrane Collaboration's tool for assessing risk of bias antiphospholipid antibodies. The rate of successful pregnancy in those with secondary abortions in thromboprophylaxis group (81.8%) was higher than the control group (0.25%) (P ¼ 0.02).
0.26, 95% CI 0.14 -0.48; Ziakas et al., 2010) . In two trials in which treatment with LMWH combined with aspirin (n ¼ 96) was compared with aspirin only (n ¼ 90), the pooled RR for pregnancy loss was 0.70, without reaching statistical significance (95% CI 0.34 -1.45; Ziakas et al., 2010) . When comparing any heparin (UFH or LMWH) combined with aspirin (n ¼ 199) with aspirin only (n ¼ 199), the beneficial effect of heparin of reducing the risk of first trimester miscarriage was maintained (RR 0.39, , with little statistical heterogeneity (I 2 10%; Ziakas et al., 2010) . Interestingly, in the studies that observed a profound effect of UFH added to aspirin, the chances of a live birth in the aspirin only arms were only 44 and 42% (Kutteh, 1996; Rai et al., 1997) . These are markedly lower than in the comparator arms of the other studies comparing LMWH and aspirin to aspirin only (Farquharson et al., 2002) or aspirin to placebo (Cowchock and Reece, 1997; Tulppala et al., 1997; Pattison et al., 2000) , in which the chances of a live birth varied between 68 and 80%, which indicates clinical heterogeneity between the trials. In a pilot randomized trial (n ¼ 26), a prospective cohort study (n ¼ 50) and a recent randomized trial (n ¼ 60), the use of LMWH and UFH (both combined with aspirin) were directly compared and the results did not suggest a difference in effects (Stephenson et al., 2004; Noble et al., 2005; Fouda et al., 2011) . In one trial, two doses of LMWH (enoxaparin 40 and 20 mg, both combined with aspirin) were compared (n ¼ 60); no difference in live birth was observed (RR 1.10, 95% CI 0.81 -1.49; Fouda et al., 2010) . To our knowledge, there are no trials that compared heparin (UFH or LMWH) combined with aspirin with no treatment or placebo.
The evidence for treatment with heparin combined with aspirin was obtained in two studies including women with three or more pregnancy losses (Kutteh, 1996; Rai et al., 1997) , and one study including women with two or more first-or second-trimester losses (Goel et al., 2006) . As a result, guidelines of the American College of Chest Physicians (ACCP) recommend UFH or LMWH combined with aspirin for women with antiphospholipid syndrome based on three or more pregnancy losses, but refrain from recommendations for women with antiphospholipid syndrome based on clinical criteria of a single late pregnancy loss or placental insufficiency (Bates et al., 2012) . Guidelines of the Royal College of Obstetricians and Gynaecologists state that 'pregnant women with antiphospholipid syndrome should be considered for treatment with low-dose aspirin combined with heparin to prevent further miscarriage', without further reference toward clinical criteria of antiphospholipid syndrome in the recommendation (Royal College of Obstetricians and Gynaecologists, 2011) .
Although evidence for a beneficial effect of heparin combined with aspirin is at hand, this is based on studies with very low numbers of women and further studies reaffirming this efficacy are warranted. Furthermore, whether the efficacy of heparin combined with aspirin is truly similar when UFH is replaced by LMWH needs to be determined, as well as the effect of antithrombotic agents in different subgroups of women with antiphospholipid syndrome based on laboratory or clinical criteria (e.g. women with one late pregnancy loss). This is in agreement with a statement from the ESHRE Special Interest Group for Early Pregnancy (SIGEP) that there is a need for an international collaborative RCT to evaluate the type and duration of thromboprophylaxis in antiphospholipid syndrome, before this treatment is used systematically in routine clinical practice (Jauniaux et al., 2006) . However, based on the currently available evidence of studies with small numbers of participants, clinicians worldwide have adopted practice to prescribe antithrombotic agents to all women with obstetric antiphospholipid syndrome. Acquiring ethical approval for such studies and finding patients who are willing to participate in such randomized trials will, therefore, be a major challenge.
Inherited thrombophilia
Little evidence is available for the effect of antithrombotic agents in women with a single pregnancy loss and inherited thrombophilia. Results from several small retrospective and prospective cohort studies in women with inherited thrombophilia, with or without previous pregnancy complications, suggest a beneficial effect of antithrombotic therapy to reduce pregnancy complications (Kupferminc et al., 2001; Leduc et al., 2007; Folkeringa et al., 2007) . These studies are heterogeneous with regard to study design and study population.
Single pregnancy loss. In a clinical trial, women with one previous pregnancy loss after 10 weeks' gestation and heterozygous factor V Leiden mutation, prothrombin G20210A mutation, or protein S deficiency, were allocated to enoxaparin 40 mg once daily (n ¼ 80) or to aspirin 100 mg (n ¼ 80; Gris et al., 2004) . Women who were treated with enoxaparin had a much higher chance of a live birth than those allocated to aspirin (86 and 29%, respectively, 57% absolute risk reduction, odds ratio 15.5, 95% CI 7-34). However, methodological issues regarding concealment of allocation, lack of generalizability due to very stringent inclusion criteria, and the fact that women who experienced an early miscarriage after randomization were not taken into account were raised (Rodger, 2004) . The results of this single study have not been implemented in recent evidence-based guidelines (Rodger, 2004; Middeldorp, 2007; Bates et al., 2012) .
With the apparent lack of evidence for the efficacy of antithrombotic therapy in women with inherited thrombophilia and a single pregnancy loss, antithrombotic agents are not recommended for this indication.
Recurrent pregnancy loss. Aspirin only: To our knowledge, no randomized controlled trials evaluating the efficacy of aspirin in women with inherited thrombophilia and recurrent pregnancy loss have been performed.
Heparin only: Only observational studies that have evaluated the outcomes of women with recurrent pregnancy loss treated with heparin compared with no treatment are available. These studies do not provide evidence for the efficacy of LMWH and should be regarded as hypothesis generating with a need for confirmation in randomized clinical trials. In a retrospective cohort study of women with three or more consecutive pregnancy losses and inherited thrombophilia, live birth was 70.2% in women treated with enoxaparin compared with 43.8% in historical control women who received no intervention (Carp et al., 2003) . It should be noted that 45% of the included women did not have an established form of thrombophilia, but were classified as such based on the presence of C677T mutation in the MTHFR gene for which the association with thrombosis and pregnancy loss is unclear (Robertson et al., 2006; Middeldorp and Levi, 2007) . In a prospective cohort study, 50 women with recurrent pregnancy loss and inherited thrombophilia (11 women also had antiphospholipid syndrome) were treated with enoxaparin (40 mg daily for single and 80 mg daily for combined thrombophilic defects; Brenner et al., 2000) . Live birth occurred in 75% of gestations, whereas this was 20% in previous pregnancies. The design of such a study has been criticized based on regression to the mean by using the previous bad pregnancy outcome as a control (Lindqvist and Merlo, 2005; Middeldorp, 2007) . In the LIVE-ENOX study, 180 women with thrombophilia and recurrent pregnancy loss were randomized to either enoxaparin 40 or 80 mg once daily (Brenner et al., 2005) . Besides inherited thrombophilia, also women with antiphospholipid antibodies, MTHFR 677TT genotype and hyperhomocysteinemia were eligible. Live birth rates in both groups were similar (84.3 and 78.3%, respectively), but as a control group was lacking, the effect of enoxaparin could not be validated.
Heparin combined with aspirin: To our knowledge, a randomized controlled trial evaluating the efficacy of heparin combined with aspirin limited to women with inherited thrombophilia and recurrent pregnancy loss has not been performed. In the SPIN, ALIFE and HABENOX studies (see the paragraph detailing unexplained recurrent pregnancy loss), small proportions of the study populations consisted of women with inherited thrombophilia (3.5, 15.7 and 24.6%, respectively; Clark et al., 2010; Kaandorp et al., 2010; Visser et al., 2011) . Unfortunately, subgroup analyses were insufficiently powered to address the effect of antithrombotic treatment in thrombophilic women, highlighting the urgent need for new randomized controlled trials.
Unexplained recurrent pregnancy loss
Several studies have investigated the efficacy of antithrombotic agents in women with unexplained recurrent pregnancy loss. Although some have reported beneficial effects of antithrombotic agents, concerns regarding study designs and external validity have been raised (Fawzy et al., 2008; Badawy et al., 2008; Zolghadri et al., 2010; Giancotti et al., 2012) . High-quality evidence was obtained by means of five randomized clinical trials (Tulppala et al., 1997; Dolitzky et al., 2006; Clark et al., 2010; Kaandorp et al., 2010; Visser et al., 2011) , of which three compared various antithrombotic agents with no treatment or placebo (Tulppala et al., 1997; Clark et al., 2010; Kaandorp et al., 2010) .
In the SPIN study (Clark et al., 2010) , 294 women with two or more unexplained pregnancy losses were randomized to enoxaparin 40 mg combined with aspirin 75 mg plus standard surveillance or standard surveillance only. No effect of the medical intervention was observed (odds ratio for successful pregnancy 0.91, 95% CI 0.52-1.59). In the ALIFE study, we randomized 364 women with two or more unexplained pregnancy losses to nadroparin 2850 IU combined with aspirin 80 mg, aspirin 80 mg only, or placebo (for aspirin) before conception or at a maximum gestational age of 6 weeks . Of these women, 299 became pregnant. The chance of live birth did not differ between the treatment groups [RR of live birth for women who became pregnant were 1.03 (95% CI 0.85-1.25) for nadroparin combined with aspirin, and 0.92 (95% CI 0.75 -1.13) for aspirin only, compared with placebo]. In an older trial, 66 women with recurrent pregnancy loss were randomized to aspirin or no treatment. The subgroup analysis of women with unexplained recurrent pregnancy loss (27 women randomized to aspirin and 27 to no treatment) showed no difference in live birth between both groups (i.e. 22 and 22 in both groups; Tulppala et al., 1997) .
Two studies randomized women to different antithrombotic treatment regimens but lacked a control arm with placebo or no treatment (i.e. LMWH with aspirin, LMWH only or aspirin only); the results showed no differences in live birth rates between these treatments (Dolitzky et al., 2006; Visser et al., 2011) .
Based on the available evidence (de Jong et al., 2013) , various guidelines now unanimously recommend against the use of antithrombotic agents in women with unexplained recurrent pregnancy loss (Royal College of Obstetricians and Gynaecologists, 2011; Bates et al., 2012;  Table I ).
Adverse effects of antithrombotic therapy
Potential adverse effects of antithrombotic therapy include bleeding, local skin reactions such as itching and swelling and the more rare complications, heparin-induced thrombocytopenia (HIT) and heparin-induced osteopenia. In a systematic review the safety of LMWH for thromboprophylaxis and treatment of venous thromboembolism in pregnancy was evaluated, including data from 2777 pregnancies (Greer and Nelson-Piercy, 2005) . As incidences of significant bleeding and allergic skin reactions were low (1.98%, 95% CI 1.50 -2.57 and 1.80%, 95% CI 1.34-2.37, respectively) and there was only one case of osteoporotic fracture and no case of HIT, the authors concluded that LMWH is safe in pregnancy.
Although the incidence of bleeding and significant bleeding is low, avoiding any such bleeding by withholding ineffective therapy is preferred. Furthermore, local skin reactions due to administration of LMWH were reported in 40% of women treated with nadroparin in the ALIFE study, and in 29% of women in a prospective observational study (Bank et al., 2003; Kaandorp et al., 2010) .
Testing for thrombophilia
Given the association between recurrent pregnancy loss and thrombophilia, a relevant question is whether testing for thrombophilia should be performed on a routine basis in this clinical setting. Understanding the possible cause of pregnancy loss provides an explanation for patients and their doctors. However, if a test result provides only insight but does not alter clinical management its yield is limited and testing should not be performed. If, however, effective treatment is available, the results of testing may identify those women in whom antithrombotic therapy increases the chance of live birth in a subsequent pregnancy.
In women with three or more pregnancy losses and antiphospholipid antibodies, antithrombotic therapy increases the chance of live birth and hence testing is indicated. Whether testing for antiphospholipid antibodies is also relevant for women with a single late pregnancy loss (.10 weeks' gestation) is arguable given the absence of evidence that these women benefit from antithrombotic agents. Likewise, testing women with a single or recurrent pregnancy loss for inherited thrombophilia in routine patient care is not indicated since it is unknown whether women with inherited thrombophilia benefit from antithrombotic agents in a subsequent pregnancy. Obtaining evidence of the efficacy of antithrombotic therapy in these women is essential, and until this evidence is available, we argue that testing for inherited thrombophilia for this indication should only be performed in the context of clinical trials (de Jong et al., 2011) .
As a result of the lack of evidence, recommendations regarding investigations in cases of (recurrent) pregnancy loss differ per guideline and per country and are listed in Table I . For example, RCOG guidelines recommend testing for antiphospholipid syndrome and inherited thrombophilia in women with previous second-trimester losses; ACCP does not recommend for or against testing for antiphospholipid syndrome in women with late pregnancy loss; and ACCP and British Society for Haematology guidelines suggest not to screen for inherited thrombophilia for women with a history of pregnancy complications (Baglin et al., 2010; Royal College of Obstetricians and Gynaecologists, 2011; Bates et al., 2012) .
Future perspectives
Although some insight into the pathophysiology of (recurrent) pregnancy loss and its association with thrombophilia has been gained, much has yet to be unravelled. The discussed mechanisms by which both acquired and inherited thrombophilia may play a causal role in the pathology of pregnancy loss are plausible as supported by the in vitro and animal studies. However, further studies investigating these mechanisms as well as verification of generated hypotheses in humans, are required. Ultimately, we need to obtain evidence from high-quality randomized clinical trials regarding benefits and harms of antithrombotic agents to increase live birth in women with both acquired and inherited thrombophilia.
Recently, the ALIFE2 study (www.trialregister.nl, NTR 3361) has started recruiting; this is a trial in which women with inherited thrombophilia and recurrent pregnancy loss will be randomized to either treatment with LMWH plus standard pregnancy surveillance or standard pregnancy surveillance only. Randomized trials investigating the effect of antithrombotic therapy in women with antiphospholipid syndrome are needed.
Conclusions
Over the past few years, a great body of evidence has been obtained in the field of (recurrent) pregnancy loss and its association with thrombophilia, but further compelling evidence is awaited. Guidelines for the management of women with recurrent pregnancy loss with or without thrombophilia are conflicting in terms of terminology and investigations, but unanimous regarding the need for further studies. In order to understand the association between thrombophilia and recurrent pregnancy loss, the mechanistic role of coagulation in reproduction has to be elucidated. For clinical practice, antithrombotic agents should not be given to women with unexplained recurrent pregnancy loss. Although antithrombotic agents for women with antiphospholipid syndrome are widely prescribed, the evidence underpinning this strategy is very limited. Randomized controlled trials investigating which women, particularly those with thrombophilia, benefit from antithrombotic therapy to increase their chance of live birth are essential. To overcome the challenges posed by conducting these clinical trials (international) collaboration and guideline adherence are required, and antithrombotic therapy should be prescribed only if recommended or in the context of such a clinical trial.
